FierceBiotechOriginal article
{"a":[{"_":"AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial","$":{"href":"/biotech/abbvies-bispecific-t-cell-engager-shows-promise-ph-3-multiple-myeloma-trial","hreflang":"en"}}]}
Phase 3positiveetentamigPositive
AI Analysis
Summary
AbbVie reported positive Phase 3 data for etentamig, a bispecific T-cell engager, demonstrating improved response rates and progression-free survival in relapsed/refractory multiple myeloma patients.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
improved response rates and progression-free survival
Importance:7/10
Sentiment:
0.85
multiple myelomabispecific T-cell engagerphase 3 dataoncology
Related Companies
Read the original article
Published by FierceBiotech on September 3, 2026 8:42 AM